WO1990014086A1 - Utilisation de derives de l'acridine dans le traitement d'infections retrovirales chez l'homme - Google Patents
Utilisation de derives de l'acridine dans le traitement d'infections retrovirales chez l'homme Download PDFInfo
- Publication number
- WO1990014086A1 WO1990014086A1 PCT/CH1990/000132 CH9000132W WO9014086A1 WO 1990014086 A1 WO1990014086 A1 WO 1990014086A1 CH 9000132 W CH9000132 W CH 9000132W WO 9014086 A1 WO9014086 A1 WO 9014086A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- acridine
- diamino
- prophylaxis
- intended
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
Definitions
- the subject of the invention is a pharmaceutical composition intended for the treatment or prophylaxis of human retrovirus infections, in particular those with a virus which generates the acquired immunodeficiency syndrome (SIDA / AIDS). It also relates to, as medicaments for the treatment or prophylaxis of such infections, the heterocyclic compounds used in these compositions.
- SIDA / AIDS acquired immunodeficiency syndrome
- HIV retrovirus (LAV / HTLV III) seems to be one of the most worrying for civilization today: it is responsible for the acquired immunodeficiency syndrome (SIDA / Engl.: AIDS). It is mainly transmitted by sexual or blood pathway, it affects a growing number of people and its spread is today described as endemic.
- AZT has the disadvantage of being unstable when heated (it is generally stored at -20 ° C), of producing side effects that are poorly tolerated by individuals weakened by the disease and of being very expensive. AZT is also insoluble in water, which limits the forms of application.
- the present invention makes it possible to advantageously fill this gap by proposing, as a medicament intended for the treatment or prophylaxis of human retrovirus infections, at least one nitrogen-heterocyclic compound chosen from 3,6-diamino-10-methyl chloride. -acridinium, 3,6-diamino-acridine and 9-amino-acridine.
- ACD-y Acridine Yellow
- the compounds used in the context of the present invention all comprise at least one amino group attached to the nitrogen heterocycle; they can be represented as follows: Acriflavine (ACF)
- the anti-retroviral activity of the compounds mentioned in the context of the present invention has been demonstrated, inter alia, on the leukemigenic virus of Friends (spleen focus forming virus / SFFV-F) during in vivo experiments described below. .
- acriflavine (ACF) was found to be significantly more effective than AZT at a dose of comparable toxicity, the proflavin (PF) with activity similar to that of AZT.
- AIDS AIDS
- the nitrogen heterocyclic compounds proposed by the invention as medicaments have the great advantage of being readily available on the market and of being remarkably stable at room temperature.
- their toxicity has been the subject of numerous investigations: it is perfectly known and the same goes for possible side effects.
- Said compounds also have the advantage of being water-soluble, which facilitates their application all the more, by the oral or intravenous route for example.
- mice from the DBA 2 strain 0.2 ml of a 1% solution of a spleen extract contaminated with the leukemigenic retrovirus from Friends was inoculated into mice from the DBA 2 strain divided into groups of eight. . About 1 hour after this injection, each infected mouse was administered, intraperitoneally, an aqueous solution of the heterocyclic compound chosen, at the doses shown in the table below. A group of 8 infected mice was kept as such as a control sample.
- a blood plasma sample was taken from the treated and untreated infected mice, and 0.1 ml of this plasma, as is, injected, respectively, after 10% and 1% dilution, into uncontaminated mice from of the DBA2 strain. This injection was done intravenously.
- the number of viruses received by the latter was determined eight days after this injection, by counting the foci of unit formation in the spleen.
- the effect of the drug substances used in this experiment was expressed by means of the report between the number of outbreaks counted following injection of plasma from infected infected mice and the number of outbreaks counted following injection of plasma from "control" mice. The values obtained are expressed logarithmically and are reported in the attached figure.
- PF proflavin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH1965/89-5 | 1989-05-25 | ||
CH196589A CH678275A5 (de) | 1989-05-25 | 1989-05-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990014086A1 true WO1990014086A1 (fr) | 1990-11-29 |
Family
ID=4222755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CH1990/000132 WO1990014086A1 (fr) | 1989-05-25 | 1990-05-22 | Utilisation de derives de l'acridine dans le traitement d'infections retrovirales chez l'homme |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU5630990A (de) |
CH (1) | CH678275A5 (de) |
WO (1) | WO1990014086A1 (de) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0375471A2 (de) * | 1988-12-19 | 1990-06-27 | Ste Civile De Recherche Newpharm | Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen |
EP0649656A1 (de) * | 1993-10-22 | 1995-04-26 | Laboratoire M. Richard | Acriflavine enthaltende Arzneimittel verwendbar zur Behandlung von Herpes und Zona |
FR2711527A1 (fr) * | 1993-10-22 | 1995-05-05 | Richard Laboratoire M | Utilisation de l'acriflavine comme agent anti HIV. |
WO1996007423A1 (fr) * | 1995-03-23 | 1996-03-14 | Oleg Viktorovich Travkin | Substance pharmaceutique immunomodulatrice |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3489837A (en) * | 1968-07-11 | 1970-01-13 | Leroy J Hyman | Synergistic antiseptic composition consisting of 9-aminoacridine hydrochloride and benzethonium chloride |
EP0196515A1 (de) * | 1985-03-14 | 1986-10-08 | Baxter Travenol Laboratories, Inc. | Photodynamische Inaktivierung von Viren in therapeutischen Proteinmischungen |
-
1989
- 1989-05-25 CH CH196589A patent/CH678275A5/fr not_active IP Right Cessation
-
1990
- 1990-05-22 AU AU56309/90A patent/AU5630990A/en not_active Abandoned
- 1990-05-22 WO PCT/CH1990/000132 patent/WO1990014086A1/fr unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3489837A (en) * | 1968-07-11 | 1970-01-13 | Leroy J Hyman | Synergistic antiseptic composition consisting of 9-aminoacridine hydrochloride and benzethonium chloride |
EP0196515A1 (de) * | 1985-03-14 | 1986-10-08 | Baxter Travenol Laboratories, Inc. | Photodynamische Inaktivierung von Viren in therapeutischen Proteinmischungen |
Non-Patent Citations (4)
Title |
---|
Biomed. & Pharmacother., Vol. 43, No. 4, 1989, Elsevier, (Paris, FR), G. MATHE et al.: "Amino Acridines Action on Friend's Retrovirus in Relation to their Molecular Ionization", pages 235-236 * |
Chem.-Biol. Interactions, Vol. 8, No. 2, 1988, Elsevier Scientific Publishing Co., (Amsterdam, NL), R. MENEGHINI: "Repair Replication of Opossum Lymphocyte DNA: Effect of Compounds that Bind to DNA", pages 113-126 * |
Life Sciences, Vol. 15, No. 1974, Pergamon Press, (US), R. GRAHAM SMITH et al.: "Agents which Inhibit Reverse Transcriptases", pages 1711-1730 * |
Mutation Research, Vol. 68, No. 3, 1979, Elsevier/North-Holland Biomedical Press, (Amsterdam, NL), P.E. CROSSEN: "The Effect of Acridine Compounds on Siter-Chromatid Exchange Formation in Cultured Human Lymphocytes", pages 295-299 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0375471A2 (de) * | 1988-12-19 | 1990-06-27 | Ste Civile De Recherche Newpharm | Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen |
EP0375471A3 (de) * | 1988-12-19 | 1992-07-08 | Ste Civile De Recherche Newpharm | Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen |
EP0649656A1 (de) * | 1993-10-22 | 1995-04-26 | Laboratoire M. Richard | Acriflavine enthaltende Arzneimittel verwendbar zur Behandlung von Herpes und Zona |
FR2711527A1 (fr) * | 1993-10-22 | 1995-05-05 | Richard Laboratoire M | Utilisation de l'acriflavine comme agent anti HIV. |
FR2711526A1 (fr) * | 1993-10-22 | 1995-05-05 | Richard Laboratoire M | Utilisation de l'Acriflavine comme agent anti herpès et anti zona. |
WO1996007423A1 (fr) * | 1995-03-23 | 1996-03-14 | Oleg Viktorovich Travkin | Substance pharmaceutique immunomodulatrice |
Also Published As
Publication number | Publication date |
---|---|
CH678275A5 (de) | 1991-08-30 |
AU5630990A (en) | 1990-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2656938B2 (ja) | dsRNAと逆転写酵素インヒビターを含んで成るHIV感染治療のための医薬組成物 | |
EP0278821B1 (de) | Verwendung von Morphinantagonisten zur Herstellung von Medikamenten mit immunmodulatorischer und antiviraler Wirkung, insbesondere bestimmt zur Behandlung von erworbenen Immunmangelzuständen | |
JPH0125A (ja) | dsRNAと逆転写酵素インヒビターを含んで成るHIV感染治療のための医薬組成物 | |
JP2720169B2 (ja) | 抗レトロウイルス活性をもつ糖タンパク処理抑制剤 | |
FR2639226A1 (fr) | Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs | |
JPH0232093A (ja) | 抗レトロウィルスジフルオロ化ヌクレオシド類 | |
WO1990014086A1 (fr) | Utilisation de derives de l'acridine dans le traitement d'infections retrovirales chez l'homme | |
EP0373986A1 (de) | Virushemmende Zusammensetzung und ihre Anwendungen | |
EP0185584B1 (de) | Verwendung des Heteropolyanions (NaSb9W21O86)18- zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von AIDS und analoger Syndrome | |
NL8105635A (nl) | Geneesmiddel met transplantaatafstotings- en/of immunologische ontstekingsremmende werking, alsmede werkwijze voor de remming van transplantaatafstoting en/of immunologische ontsteking. | |
WO2017174593A1 (fr) | Nouvelles compositions antivirales pour le traitement de la grippe | |
FR2713487A1 (fr) | Solutions de type homéopathique contenant un acide nucléique utilisables notamment dans la prévention ou le traitement de maladies infectieuses ou de maladies impliquant le dysfonctionnement d'un gène. | |
EP0722325A1 (de) | Zusammensetzung zur behandlung oder vorbeugung von herpes | |
CH679982A5 (en) | Anti-retroviral compsn. contg. 2-methyl-9-hydroxy-ellipticine acetate - esp. for treatment or prevention of AIDS with greater activity than AZT | |
Mathov | The risks of monoamine oxidase inhibitors in the treatment of bronchial asthma | |
JPH0415766B2 (de) | ||
FR2618676A1 (fr) | Compositions pharmaceutiques antivirales | |
EP0841909B1 (de) | Verwendung von alicyclischen diaminen als immunomodulatoren | |
CH684521A5 (fr) | Composition thérapeutique comportant un complexe de l'acide polyadenylique avec l'acide polyuridylique. | |
JPH04502905A (ja) | 新規抗ウイルス剤 | |
EP1001789B1 (de) | Zusammensetzung die mindestens einem doppel strangiger rna mit mindestens einem 6-benzyluracile derivat enthält für eine gleichzeitige, getrennte oder zeitausgelegte therapeutische verwendung | |
FR2640508A1 (fr) | Nouvelles compositions et nouveaux produits pharmaceutiques assurant la regeneration de leucocytes et leur emploi pour le traitement du syndrome immuno-deficitaire | |
CA1307740C (en) | Pharmaceutical preparation and method for inhibiting replication of htlv-iii (aids) virus | |
JPH07509442A (ja) | ウィルス病処置でのホスホリル化フラボノイド類 | |
KR940006591A (ko) | 비루스성 감염치료 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB IT LU ML MR NL SE SN TD TG |
|
NENP | Non-entry into the national phase in: |
Ref country code: CA |